More articles from Prostate Cancer Imaging II

You have access
⁶⁸Ga-RM2 PET/MRI Detection of Recurrent Prostate Cancer in Patients with Negative Conventional Imaging
Lucia Baratto, Caitlyn Harrison, Guido Davidzon, Tommy Yohannan and Andrei Iagaru

Journal of Nuclear Medicine May 1, 2018, 59 (supplement 1) 453;
You have access
[¹⁸F]PSMA-1007 PET/CT in 166 Patients with BCR after radical prostatectomy
Frederik Giesel, Karina Knorr, Fabian Spohn, Tobias Maurer, Gregor Habl, Clemens Kratochwil, Uwe Haberkorn, Klaus Kopka, Oliver Neels, Wolfgang Weber, Markus Schwaiger and Matthias Eiber

Journal of Nuclear Medicine May 1, 2018, 59 (supplement 1) 459;
You have access
⁶⁸Ga-PSMA PET/CT for primary diagnosis of prostate cancer in men with contraindications to or negative mpMRI
Egesta Lopci, Massimo Lazzeri, Giovanni Lughezzani, Piergiuseppe Colombo, NiccolÃ² Buffi, Rodolfo Hurle, Alberto Saita, Roberto Peschechera, Alessio Benetti, Silvia Zandegiacomo, Luisa Pasini, Giuliana Lista, Paolo Casale, Angelo Castello, Luca Balzarini, Arturo Chiti and Giorgio Guazzoni

Journal of Nuclear Medicine May 1, 2018, 59 (supplement 1) 454;
You have access
Spatial colocalization of ¹⁸F-DCFPyL PET/CT and ¹⁸F-NaF PET/CT within prostate cancer bone metastases
Stephanie Harmon, Esther Mena, Marcin Czarniecki, Stephen Adler, Anita Ton, Ravi Madan, James Gulley, William Dahut, Ronnie Mease, Martin Pomper, Ismail Turkbey, Peter Choyke and Maria Liza Lindenberg

Journal of Nuclear Medicine May 1, 2018, 59 (supplement 1) 455;
You have access
⁶⁸Ga-PSMA11 PET/CT localizes recurrent prostate cancer with high accuracy: preliminary results from a phase 2/3 prospective trial
Wolfgang Fendler, Jeremie Calais, Jeannine Gartmann, Nicholas Nickols, Robert Reiter, Matthew Rettig, Thomas Hope, Roger Slavik, Pawan Gupta, Andrew Quon, Martin Allen-Auerbach, Ken Herrmann, Johannes Czernin and Matthias Eiber

Journal of Nuclear Medicine May 1, 2018, 59 (supplement 1) 456;
You have access
Performance of the novel ¹⁸F-labeled prostate-specific membrane antigen-ligand PSMA-7 for PET/CT in prostate cancer patients
Markus Dietlein, Melanie Hohberg, Carsten Kobe, Felix Dietlein, Boris Zlatopolskiy, Philipp Krapf, Bernd Neumaier and Alexander Drzezga

Journal of Nuclear Medicine May 1, 2018, 59 (supplement 1) 452;
You have access
A prospective, multinational comparison of multi-parametric and whole body magnetic resonance imaging (mp-MRI and WB- MRI) F-18 fluoro-methyl-choline (FCH) and Ga-68 HBED-CC- (PSMA) in high risk men being considered for salvage radiation treatment for biochemical failure post radical prostatectomy: Detection rates, management impact and treatment response.
Louise Emmett, Ur Metser, Glenn Bauman, Rodney Hicks, Frederic Pouliot, Ian Davis, Sue Chua, Andrew Weickhardt, Shonit Punwani, Bao Ho, Edward Johnston and Andrew Scott

Journal of Nuclear Medicine May 1, 2018, 59 (supplement 1) 458;
You have access
Evaluation of PSMA-based ¹⁸F-DCFPyL PET/CT imaging in patients with biochemical recurrence prostate cancer after primary local therapy
Esther Mena, Ismail Turkbey, Maria Liza Lindenberg, Stephanie Harmon, Marcin Czarniecki, Stephen Adler, Anita Ton, Philip Eclarinal, Alicia Forest, Juanita Weaver, Yolanda McKinney, Deborah Citrin, William Dahut, Anna Couvillon, Ronnie Mease, Martin Pomper and Peter Choyke

Journal of Nuclear Medicine May 1, 2018, 59 (supplement 1) 451;
You have access
¹⁸F-Fluciclovine PET/CT in patients with biochemical recurrence of prostate cancer: Impact on management and associations of clinical variables with scan findings
Austin Pantel, Eleanor Gillis, Barry Siegel and David Mankoff

Journal of Nuclear Medicine May 1, 2018, 59 (supplement 1) 457;

Main menu

User menu

Search

More articles from Prostate Cancer Imaging II